Fate Therapeutics Management
Management criteria checks 1/4
Fate Therapeutics' CEO is Bob Valamehr, appointed in Jan 2025, has a tenure of less than a year. total yearly compensation is $3.58M, comprised of 14.6% salary and 85.4% bonuses, including company stock and options. directly owns 0.07% of the company’s shares, worth $96.90K. The average tenure of the management team and the board of directors is 0.4 years and 15.1 years respectively.
Key information
Bob Valamehr
Chief executive officer
US$3.6m
Total compensation
| CEO salary percentage | 14.65% |
| CEO tenure | less than a year |
| CEO ownership | 0.07% |
| Management average tenure | less than a year |
| Board average tenure | 15.1yrs |
Recent management updates
Recent updates
Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector
May 08We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Apr 22
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
Feb 05We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Jan 06Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
Nov 20Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts
Aug 21Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Aug 11Fate Therapeutics: Looking For A Potential Turnaround In 2024
Apr 29Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 23Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%
Feb 16Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks
Jan 26Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry
Dec 19Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?
Sep 08Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price
Jun 07Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%
May 08Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Apr 17We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
Jan 10Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Sep 22Fate Therapeutics: Yes For Speculators, No For Defensive Investors
Aug 30Needham initiates Fate coverage Therapeutics on potential of stem cell therapies
Jul 28Fate Therapeutics names Brian Powl as chief commercial officer
Jun 30Fate: Possible Speedy FDA Approval Process With RMAT Designation
Jun 03We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
Jun 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$176m |
| Dec 31 2024 | US$4m | US$525k | -US$186m |
| Sep 30 2024 | n/a | n/a | -US$178m |
| Jun 30 2024 | n/a | n/a | -US$176m |
| Mar 31 2024 | n/a | n/a | -US$190m |
| Dec 31 2023 | US$3m | US$500k | -US$161m |
| Sep 30 2023 | n/a | n/a | -US$173m |
| Jun 30 2023 | n/a | n/a | -US$212m |
| Mar 31 2023 | n/a | n/a | -US$235m |
| Dec 31 2022 | US$3m | US$455k | -US$282m |
| Sep 30 2022 | n/a | n/a | -US$294m |
| Jun 30 2022 | n/a | n/a | -US$254m |
| Mar 31 2022 | n/a | n/a | -US$233m |
| Dec 31 2021 | US$6m | US$430k | -US$212m |
| Sep 30 2021 | n/a | n/a | -US$197m |
| Jun 30 2021 | n/a | n/a | -US$212m |
| Mar 31 2021 | n/a | n/a | -US$185m |
| Dec 31 2020 | US$2m | US$390k | -US$173m |
| Sep 30 2020 | n/a | n/a | -US$149m |
| Jun 30 2020 | n/a | n/a | -US$117m |
| Mar 31 2020 | n/a | n/a | -US$112m |
| Dec 31 2019 | US$3m | US$375k | -US$98m |
| Sep 30 2019 | n/a | n/a | -US$86m |
| Jun 30 2019 | n/a | n/a | -US$76m |
| Mar 31 2019 | n/a | n/a | -US$72m |
| Dec 31 2018 | US$3m | US$322k | -US$67m |
Compensation vs Market: Bob's total compensation ($USD3.58M) is above average for companies of similar size in the US market ($USD646.03K).
Compensation vs Earnings: Bob's compensation has increased whilst the company is unprofitable.
CEO
Bob Valamehr (48 yo)
Dr. Bahram Valamehr, also known as Bob, Ph D, M.B.A., is President and CEO of Fate Therapeutics, Inc. since January 01, 2025 and serves as its Director since January 2025 and was its President of Research...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$3.58m | 0.070% $ 96.9k | |
| Chief Legal & Compliance Officer and Corporate Secretary | 9.7yrs | US$3.42m | 0.059% $ 81.6k | |
| Vice President of Corporate Development & Finance | less than a year | no data | no data | |
| Vice President Of Human Resources & Operations | less than a year | no data | no data | |
| Senior Vice President of Clinical Operations | 1.4yrs | no data | no data | |
| Senior Vice President of Technical Operations | less than a year | no data | no data | |
| Head of Intellectual Property & Assistant General Counsel | less than a year | no data | no data | |
| Corporate Controller | less than a year | no data | no data |
Experienced Management: FATE's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$3.58m | 0.070% $ 96.9k | |
| Independent Chairman | 13.6yrs | US$197.42k | 0.54% $ 747.1k | |
| Independent Vice Chairman of the Board | 17.2yrs | US$160.92k | 0.27% $ 376.6k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 11.3yrs | US$172.42k | 0.0099% $ 13.7k | |
| Member of Scientific Advisory Board | 15.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 15.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 15.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 15.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 15.1yrs | no data | no data | |
| Independent Director | 6.3yrs | US$172.92k | 0.0086% $ 11.9k |
Experienced Board: FATE's board of directors are seasoned and experienced ( 15.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/02 14:30 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fate Therapeutics, Inc. is covered by 28 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Peter Lawson | Barclays |
| James Birchenough | BMO Capital Markets U.S. (Historical) |